Antibody-drug conjugates (ADCs) hold great promise for the targeted treatment of cancer, and the market is expected to grow significantly in the upcoming years driven by the continued breakthroughs in ADC technologies.
In this CRA Insights, the authors breakdown some of the key challenges faced by ADCs from the manufacturing, reimbursement, and clinical perspectives. They have highlighted the importance of manufacturers to take a broad, cross-functional view of how to best position ADCs for medical, commercial, and pricing success, leveraging synergies where possible to address stakeholders’ key concerns. Click here to read more about Antibody-drug conjugates.
